Evidence map›Paper›PMID 25346790›Full record

ArticleCommunicative & integrative biology2014

On the origin of giant cells in Hodgkin lymphoma.

Benjamin Rengstl, Michael A Rieger, Sebastian Newrzela

Open access · goldAbstract read
In one paragraph

Article in Communicative & integrative biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Benjamin RengstlDr. Senckenberg Institute of Pathology; Goethe-University of Frankfurt Medical School; Frankfurt am Main, Germany.
Michael A RiegerLOEWE Center for Cell and Gene Therapy Frankfurt; Department of Hematology/Oncology; Goethe-University of Frankfurt Medical School; Frankfurt am Main, Germany ; German Cancer Consortium (DKTK); Heidelberg, Germany ; German Cancer Research Center (DKFZ); Heidelberg, Germany.
Sebastian NewrzelaDr. Senckenberg Institute of Pathology; Goethe-University of Frankfurt Medical School; Frankfurt am Main, Germany.
Goethe University Frankfurt · DESenckenberg Research Institute and Natural History Museum Frankfurt/M · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multinucleated giant tumor cells are frequently observed in tissue sections of lymphoma patients. In Hodgkin lymphoma (HL), these cells are pathognomonic for the disease and named Reed-Sternberg (RS) cells. Despite the well-described disease-promoting functions of RS cells, their development has remained obscure. We addressed this open question by continuous live cell imaging to observe the generation of RS cells. Single-cell tracking of HL cell lines revealed that RS cells develop from mononucleated progenitors that divide and subsequently re-fuse, before they grow and become multinucleated giant cells. Thus, RS cell generation is neither due to cell fusion of unrelated Hodgkin cells nor to endomitosis, as previously suggested. In the majority of cases, re-fusion of daughter cells was preceded by an incomplete cytokinesis, visualized by a persistent microtubule bridge connecting the cells. This surprising finding describes a novel mechanism for the formation of multinuclear giant cells with potential relevance beyond HL.

Indexed as

acytokinetic mitosiscell fusionendomitosisgiant cellsHodgkin lymphomaincomplete cytokinesisReed-Sternberg cellsre-fusionsingle-cell trackingtime-lapse microscopy

Identifiers

PMID25346790
PMCPMC4203491
OpenAlexW2028771287

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.